Sebastian J C Neggers

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. pmc Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
    Sebastian J C M M Neggers
    Department of EndocrinologyErasmus Medical Center, Rotterdam, NetherlandsDepartment of EndocrinologyI M Sechenov First Moscow State Medical University, Moscow, Russian FederationDepartment of EndocrinologyPauls Stradins Clinical University Hospital, Riga, LatviaDivision of Endocrinology and MetabolismSamsung Medical Center, Sungkyunkwan University, Seoul, Republic of KoreaDepartment of Neuroendocrinology and Bone DiseasesNational Endocrinology Research Centre, Moscow, Russian FederationNeuroendocrine UnitDivision of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, BrazilEndocrine SectionHospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilIpsen Boulogne BillancourtFrance
    Eur J Endocrinol 173:313-23. 2015
  2. doi request reprint Medical approach to pituitary tumors
    S J C M M Neggers
    Section of Endocrinology, Department of Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands Electronic address
    Handb Clin Neurol 124:303-16. 2014
  3. doi request reprint What is active acromegaly and which parameters do we have?
    S J C M M Neggers
    Department of Medicine, Section Endocrinology, Erasmus University Medical Center Rotterdam, CA Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 76:609-14. 2012
  4. ncbi request reprint Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly
    Sebastian J C M M Neggers
    Department of Internal Medicine, Erasmus University MC Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 92:4598-601. 2007
  5. doi request reprint Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant
    S J C M M Neggers
    Department of Internal Medicine, Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 93:3853-9. 2008
  6. doi request reprint Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients
    S J C M M Neggers
    Department of Medicine, Erasmus University, Erasmus MC, Rotterdam, The Netherlands
    Eur J Endocrinol 160:529-33. 2009
  7. doi request reprint Somatostatin analog and pegvisomant combination therapy for acromegaly
    Sebastian J C Neggers
    Department of Medicine, Endocrinology Section, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Nat Rev Endocrinol 5:546-52. 2009
  8. pmc Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
    Sebastian J C M M Neggers
    Department of Medicine, Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
    Pituitary 14:253-8. 2011
  9. doi request reprint Combination treatment with somatostatin analogues and pegvisomant in acromegaly
    S J C M M Neggers
    Department of Medicine, Section Endocrinology, Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Growth Horm IGF Res 21:129-33. 2011

Detail Information

Publications9

  1. pmc Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
    Sebastian J C M M Neggers
    Department of EndocrinologyErasmus Medical Center, Rotterdam, NetherlandsDepartment of EndocrinologyI M Sechenov First Moscow State Medical University, Moscow, Russian FederationDepartment of EndocrinologyPauls Stradins Clinical University Hospital, Riga, LatviaDivision of Endocrinology and MetabolismSamsung Medical Center, Sungkyunkwan University, Seoul, Republic of KoreaDepartment of Neuroendocrinology and Bone DiseasesNational Endocrinology Research Centre, Moscow, Russian FederationNeuroendocrine UnitDivision of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, BrazilEndocrine SectionHospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilIpsen Boulogne BillancourtFrance
    Eur J Endocrinol 173:313-23. 2015
    ..To evaluate extended dosing intervals (EDIs) with lanreotide Autogel 120 mg in patients with acromegaly previously biochemically controlled with octreotide LAR 10 or 20 mg...
  2. doi request reprint Medical approach to pituitary tumors
    S J C M M Neggers
    Section of Endocrinology, Department of Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands Electronic address
    Handb Clin Neurol 124:303-16. 2014
    ..In acromegaly and TSH-secreting adenomas medical treatment has a more prominent role than in Cushing's disease. In this chapter the efficacy and side-effects of the different medical therapies is discussed according to adenoma type. ..
  3. doi request reprint What is active acromegaly and which parameters do we have?
    S J C M M Neggers
    Department of Medicine, Section Endocrinology, Erasmus University Medical Center Rotterdam, CA Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 76:609-14. 2012
    ..Both GH and IGF1 have been associated with prognosis, in particular mortality. In this review, we discuss the available parameters to assess disease activity in acromegaly...
  4. ncbi request reprint Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly
    Sebastian J C M M Neggers
    Department of Internal Medicine, Erasmus University MC Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 92:4598-601. 2007
    ..We previously reported the efficacy of a combined treatment of active acromegaly with both long-acting somatostatin analogs (SSA) and pegvisomant (PEG-V)...
  5. doi request reprint Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant
    S J C M M Neggers
    Department of Internal Medicine, Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 93:3853-9. 2008
    ....
  6. doi request reprint Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients
    S J C M M Neggers
    Department of Medicine, Erasmus University, Erasmus MC, Rotterdam, The Netherlands
    Eur J Endocrinol 160:529-33. 2009
    ..We previously reported on the efficacy, safety, and quality of life (QoL) of long-acting somatostatin analogs (SSA) and (twice) weekly pegvisomant (PEG-V) in acromegaly and improvement after the addition of PEG-V to long-acting SSA...
  7. doi request reprint Somatostatin analog and pegvisomant combination therapy for acromegaly
    Sebastian J C Neggers
    Department of Medicine, Endocrinology Section, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Nat Rev Endocrinol 5:546-52. 2009
    ..In this Review, we discuss the available data on the long-term efficacy and safety of somatostatin analog-pegvisomant combination treatment and its potential use in patients with acromegaly...
  8. pmc Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
    Sebastian J C M M Neggers
    Department of Medicine, Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
    Pituitary 14:253-8. 2011
    ..However, there seems to be a wide variation in the reduction of PEG-V dose, which can be obtained after conversion to combined treatment...
  9. doi request reprint Combination treatment with somatostatin analogues and pegvisomant in acromegaly
    S J C M M Neggers
    Department of Medicine, Section Endocrinology, Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Growth Horm IGF Res 21:129-33. 2011
    ..Transient elevations in the levels of transaminases are the main adverse effects of combination treatment, which occur in about 11-15% of patients...